17Q1

PHARMARON BEIJING H YC1

Healthcare · EUR · F

17Q1

Price

€1.972

-3.10%

Cap

€3.71B

Earnings

30d Trend

-12.2%

17Q1
Loading chart data...
0 days · % change from startPowered by Brain47
VolatilityHigh

49% annualised over 90 days

BRAIN47 SIGNAL

0
STRONG
Risk Level65
Quality71
Momentum69
Technical39
Fundamentals90

Raw weighted: 67×Macro 0.99 (1%)=66

RISK

65/100
90d Volatility
49.0%High
ATR %
2.5%Normal
Max Drawdown (1Y)
-41.4%Volatile

QUALITY

71/100
ROE (avg)
10.0%Weak
Piotroski F-Score
6/9Average
Margin Stability
CV 2.7%Very stable
Accruals
-5.7%Cash earnings
Interest Coverage
11.5xVery comfortable

MOMENTUM

69/100
12-1M Momentum
+33.6%Strong uptrend
6-1M Momentum
-3.0%Flat
1M Return
-16.0%Sharp decline

TECHNICAL

39/100
RSI (14)
40.3Neutral
Price vs SMA200
-17.1%Bearish trend
MACD
-0.01Bearish momentum
Bollinger Band
25%Mid-range
SMA Cross
Golden CrossGolden Cross
Trend Quality (KER)
0.259Noisy/choppy

FUNDAMENTALS

90/100
EV/EBIT
1.2Cheap
P/FCF
6.7Cheap
P/S
0.3Cheap
Shareholder Yield
14.3%Strong returns

Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%

Running historical backtest...

BRAIN47 HORIZON ANALYSIS

<3 months38
3-12 months33
1-5+ years73

Long-term compounder with 14.3% yield

BRAIN47'S ASSESSMENT

I rate PHARMARON BEIJING H YC1 at 66/100 — a STRONG reading on the Brain47 Signal. The strongest factor is fundamentals at 90/100. I classify this as a income position with the strongest thesis on a long-term horizon.

PAST PERFORMANCE

1 MONTH

-16.0%

3 MONTHS

-5.5%

12 MONTHS

+17.6%

Trailing returns — past performance, not a projection.

DETAILED ANALYSIS

Long-term compounder with 14.3% yield. Fundamentals (90) and Quality (71) are the primary strengths. I note an elevated risk profile — this warrants closer monitoring. Historical volatility is elevated at 49%. I classify this as an income position — the 14.3% yield combined with the dividend profile makes it suitable for income generation.

incomeScore: 66/100

Want full analysis on every stock?

Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.

Join Brain47 — Free

Generated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.